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Gender identity describes one’s psychological understanding of themselves as female, male, 
both, or neither (American Psychological Association, 2015). Transgender (trans) people are 
those whose gender identity or presentation is incongruent with the typical gender constructs 
of their birth-assigned sex (American Psychological Association, 2015; Bockting, 2009; 
Bockting, Miner, Swinburne Romine, Hamilton, & Coleman, 2013; Hendricks & Testa, 2012; 
Mayer et al., 2008). While many trans people identify with one of two orthogonal gender 
groups (trans men and trans women), an increasing number of people identify somewhere 
between the female and male poles of the gender identity spectrum and may describe 
themselves as non-binary, genderqueer, androgynous or two-spirit (American Psychological 
Association, 2015; Carroll, Gilroy, & Ryan, 2002; Eyler, 2007; Hendricks & Testa, 2012). 
Few studies have sought to measure the population prevalence of trans identity—those that 
have provide estimates for the United Kingdom (UK) (0.3–0.76%; Glen & Hurrell, 2012; 
Government Equalities Office, 2018), Belgium (0.6%; Van Caenegem et al., 2015), New 
Zealand (1.2%; Clark et al., 2014), the Netherlands (0.9%; Kuyper & Wijsen, 2014), and the 
United States (U.S.) (0.4–0.6%; Conron, Scott, Stowell, & Landers, 2012; Meerwijk & 
Sevelius, 2017; Reisner et al., 2016). Extrapolation from the lower end of these estimates 
(0.5%) suggests that there are as few as 25 million trans people worldwide (Winter et al., 
2016). Consequently, trans people experience high levels of stigma, which typically 
manifests as peer or familial rejection alongside any combination of verbal, sexual or 
physical violence (Flores, Herman, Gates, & Brown, 2016; Kidd, Veltman, Gately, Chan, & 
Cohen, 2011; Stieglitz, 2010; Stotzer, 2009).  
Rates of transphobic violence appear to be increasing. In the UK, the number of transphobic 
hate crimes reported annually has tripled since 2014 and a survey of trans youth in Scotland 
found that 73% of respondents reported experiencing at least one type of specifically 
transphobic emotionally abusive behavior from a current or ex-partner (LGBT Youth 
Scotland & Equality Network, 2010; Marsh, Mohdin, & McIntyre, n.d.). Similarly, in the U.S., 
up to an estimated 89% of trans people are at risk of gender-based violence (Wirtz, Poteat, 
Malik, & Glass, 2018). Prior research has strongly associated surviving violence of this 
nature with increased rates of alcohol (Arayasirikul, Wilson, & Raymond, 2017; Chakrapani, 
Newman, Shunmugam, Logie, & Samuel, 2017; Nuttbrock et al., 2014) and illicit drug use 
(Budhwani et al., 2017; Scheim, Bauer, & Shokoohi, 2017; Shah et al., 2018), as well as 
nonmedical use of prescription drugs (Benotsch et al., 2013). 
This heightened risk for substance use is compounded by stigmatizing and frequently 
cisnormative substance misuse treatment systems that contribute to up to 50% of trans 
people delaying or avoiding seeking treatment (Cochran & Cauce, 2006; Eliason, 2000; 
Lombardi & van Servellen, 2000; Nuttbrock, 2012; Sperber, Landers, & Lawrence, 2005). 
One qualitative study describes how treatment dropout was common among trans 
participants because providers restricted them to facilities congruent with their natal-
assigned sex and tolerated both threats of and acted-upon transphobic violence (Lyons et 
al., 2015). Further, surveys have demonstrated that only 5% of substance misuse service 
providers have formal education about the needs of trans clients and service providers have 
often made the incorrect assumption that “all transgender people are gay.” Therefore, poor 
care likely results from a lack of knowledge among nonspecialist services providers 
(Cochran, Peavy, & Cauce, 2007; Eliason, 2000; Rachlin, Green, & Lombardi, 2008).  
Almost 20 years ago there was a call for the development of specialist substance misuse 
services so that gender and sexual minorities could circumvent the stigma and discrimination 
faced in general treatment services (Lombardi & van Servellen, 2000). However, a recent 
systematic review found evidence of only two such interventions, both of which were 
narrowly aimed at trans women in the U.S., with a primary aim of human immunodeficiency 
virus (HIV) risk reduction  (Glynn & van den Berg, 2017).  
In light of the long-standing barriers faced by trans people seeking substance misuse 
healthcare, this study used a large, international, cross-sectional dataset to compare 
intentions to reduce substance use and seek help across five gender groups (cis women, cis 
men, trans women, trans men, and non-binary people). This paper builds on previous work 
with similar methodology that was limited because it considered the needs of only cisgender 
people (Davies, Maier, Winstock, & Ferris, 2019). 
 
2. Methods 
2.1. Study design 
Data collected from the 2018 and 2019 Global Drug Surveys (GDS), conducted between 
November 8, 2017 and December 30, 2018; and between October 29, 2018 and December 
30, 2018, respectively, were used for this analysis. The GDS is the world’s largest annual, 
self-administered, internet-based survey designed to evaluate existing and emerging 
patterns of substance use; it is developed by an international committee of multidisciplinary 
substance use experts (Barratt et al., 2017).  
The GDS uses a nonprobabilistic technique, purposive sampling, to recruit its participants 
through extensive collaboration with partners such as The Guardian, Fairfax media, Mixmag, 
and global social media networks such as Facebook and Twitter. The 2018 and 2019 
versions of the survey were available in 19 languages, reached more than 40 countries and 
on each occasion more than 120,000 participants were recruited. A thorough account of 
GDS recruitment techniques and methodology is discussed elsewhere (Barratt et al., 2017). 
The focus of this paper is comparing the intention to reduce substance use and to seek help 
between trans and cis GDS respondents. The 2018 and 2019 datasets were pooled to 
increase the sample of trans respondents, and in turn the power of these analyses. To 
minimize the chance of duplicate entries, all GDS 2019 participants who responded “yes” or 
were missing on the item “Have you taken part in the GDS before?” were deleted from the 
2019 dataset prior to merging. To provide context, findings from a forthcoming paper are 
also presented. The aforementioned five gender groups are compared on a) last 12-month 
use of a range of substances and b) self-reported probable dependence on those 
substances. However, these latter findings are derived from GDS 2018 only because 
substance dependence (Severity of Dependence Scale) was not measured in GDS 2019 
(Gossop et al., 1995).  
Ethical approval was received from University College London 11671/001: Global Drug 
Survey, The University of New South Wales (HREC HC17769), and University of 




Gender was assessed using a two question approach (Bauer, Braimoh, Scheim, & Dharma, 
2017; Sausa, Sevelius, Keatley, Iniguez, & Reyes, 2009). The first question concerns gender 
assigned at birth and participants could choose between “male” and “female”. The second 
focused on each participant’s current gender identity and included the following response 
options: male, female, non-binary, or different identity. While the meaning of “different 
identity” was not pre-specified, we assumed that respondents were most likely to endorse 
this option if their gender did not fit within either orthogonal gender category and was 
described with a term other than “non-binary”. As such, non-binary and different identity 
groups were combined, to create a group that encompasses the many gender identities 
between the male and female poles of the gender identity spectrum. Each participant’s 
responses to these questions were combined, which resulted in their assignment to one of 
five gender groups: cis woman, cis man, trans woman, trans man, or non-binary. The final 
sample across the two years included 2,579 trans participants. The criteria for each group 
are summarized in Table 1. Participants were considered trans if their answers to questions 
one and two were different, marked with an asterisk in Table 1 (Bauer et al., 2017). 
[INSERT TABLE 1] 
2.2. Substances considered and help-seeking variables 
The pooled GDS dataset included data on the use of nine substances: alcohol, cannabis, 
ecstasy/3,4-methylenedioxymethamphetamine (MDMA), cocaine, amphetamine powder, 
amphetamine paste, methamphetamine, ketamine, and synthetic cannabinoids. If 
participants endorsed use of any of these substances they were asked, “Would you like to 
use less [substance] over the next 12 months?” and “Would you like help to use less 
[substance] over the next 12 months?” 
The incidence of alcohol and cannabis use far exceeded that of other substances. As such, 
composite “illicit drugs” variables were created, where responses to the above questions 
were combined for all substances except alcohol and cannabis (which were considered 
individually and separately)i. For each question, a positive endorsement for one or more of 
the component substances was sufficient to positively endorse the composite variable.   
 
2.3. Statistical analyses 
All analyses were conducted using IBM SPSS Statistics software, version 25 (International 
Business Machines Corporation, 2018).  
Using the GDS 2018 dataset, separate binary logistic regression models generated odds 
ratios for the association between gender and last 12-month substance use and substance 
dependence, where cis women were the reference group. For each of the help-seeking 
variables in the combined GDS 2018 and 2019 dataset, the number of participants in each 
gender group who responded “yes” was reported as a count and as a percentage of the total 
number of participants who responded to that question. Likelihood-ratio Chi-square analyses 
were applied as an omnibus test for differences in help-seeking variables across all five 
gender groups. Z-tests with Bonferroni correction were then applied to test for differences 
between each individual gender group at the level p<0.05.  
3. Results 
3.1. Sample composition 
The total number of participants that responded to both gender questions was 185,055 
(2,579; 1.4% trans) in the pooled dataset and 126,648 (1,710; 1.35%) in GDS 2018. The 
distribution of these participants across the five gender groups is summarized in Table 1. In 
the pooled sample, the largest group of respondents originated from Germany (n=66,977, 
36.2%), followed by Denmark (n=17,708, 9.6%), the U.S. (n=11,494, 6.2%), New Zealand 
(n=7,630, 4.1%), and Poland (n=7,492, 4.0%). Nearly half (49.5%) of this sample was <25 
years old. Sexual orientation was reported by only 66.3% (122,655) of the pooled sample. 
The low response rate is likely because the sexual orientation question was among the final 
questions, when some respondents had already ended their participation. Among cis 
responses, heterosexual was most common (83.7%), followed by bisexual (10.8%), 
homosexual (4.4%), and “other” (1.2%). Trans respondents were most likely to report a 
bisexual orientation (39.8%), followed by “other” (25.7%), heterosexual (19.7%), then 
homosexual (14.9%). 
 
3.2. Psychoactive substance use and help-seeking analyses 
Comparative analyses of substance use and dependence among cis and trans GDS 2018 
respondents demonstrated increased risk among trans respondents. Specifically, non-binary 
participants, the highest risk gender group, reported the greatest odds of last 12-month use 
of all illicit substances (OR 1.66–2.93, relative to cis women) and the greatest odds of 
dependence on cannabis (OR 2.39) and alcohol (OR 3.28). Trans women had greater odds 
of reporting dependence on “novel psychoactive substances” (mephedrone, ketamine, and 
synthetic cannabinoids) than any other gender group (OR 4.60). These analyses will be 
presented in full in a forthcoming paper. 
In the help-seeking analyses using the combined GDS 2018 and 2019 dataset (presented in 
Table 2), cis men were significantly more likely than cis women to report wanting to use less 
alcohol (34.0% vs 30.8%) and cannabis (30.9% vs 26.5%) in the next 12 months. However, 
trans men, trans women, and non-binary people did not differ significantly from any group on 
these measures. There were no significant differences between any gender groups on the 
composite measure assessing the desire to use illicit drugs less. 
For both alcohol and cannabis, non-binary people had the greatest percentage of help-
seekers among those wanting to use less (14.0% and 21.3% respectively). The proportion of 
help-seeking among non-binary people was significantly higher than among cis men and cis 
women but not significantly different from trans men or trans women.  
For illicit drugs, trans women had the greatest percentage of help-seekers among those 
wanting to use less (30%). This was significantly higher than among cis men (9.6%) and cis 
women (10.4%), but not significantly different from trans men (12.5%) or non-binary people 
(16.3%). 
[INSERT TABLE 2]  
 
4. Discussion 
4.1. Key findings 
This study found that there were no significant differences between trans and cis participants 
on the desire to reduce psychoactive substance use in the subsequent 12 months. However, 
on the variable, “Would you like help to use less [substance] over the next 12 months?”, 
there were statistically, and potentially clinically meaningful, differences observed between 
trans and cis participants. Analysis of this variable was divided into three categories: alcohol, 
cannabis, and illicit drugs. In two of these analyses (cannabis and alcohol), non-binary 
people reported the greatest need for help; and in the third (illicit drugs), trans women 
reported the greatest need for help. In addition, there appeared to be a trend of increasing 
risk, where cis women were the lowest risk groups and escalating risk was observed in cis 
men, followed by trans men, trans women, and non-binary people as the highest risk group.  
 
4.2. Findings in context 
Considering these findings in context, there is a nascent literature that demonstrates an 
increased risk for binge drinking (Messman & Leslie, 2019; Scheim, Bauer, & Shokoohi, 
2016), harmful drinking (Staples, Neilson, George, Flaherty, & Davis, 2018; Tupler et al., 
2017), and illicit drug use (Hebbar, Nagaraj, & Singh, 2018; Scheim et al., 2017) among 
trans people, relative to cis counterparts. This literature is in keeping with the substance use 
and dependence analyses from GDS 2018 and could explain the differences in the desire for 
help to reduce substance use observed in the GDS samples. These differences may also be 
a function of the barriers to treatment described above (Cochran & Cauce, 2006; Eliason, 
2000; Lombardi & van Servellen, 2000; Nuttbrock, 2012; Rachlin et al., 2008; Sperber et al., 
2005), whereby trans people are reporting a need for help more frequently than cis people 
because they lack accessible, inclusive substance misuse services and are expressing a 
need for an alternative source of support, such as gender-affirmative LGBT+ peer support 
groups (Matsuzaka, 2018). 
 
4.3. Strengths and limitations 
The greatest strength of this study is its sample size. GDS 2019 followed by GDS 2018 
represent the largest reported samples of trans participants with cis comparators in the 
substance misuse literature. While five other studies in the substance misuse literature 
report on trans samples with ≥1,000 participants, none of these included cis participants and 
so could not make between-group comparisons (Gonzalez, Gallego, & Bockting, 2017; Klein 
& Golub, 2016; Reback & Fletcher, 2014; Reisner et al., 2015; Yi et al., 2017). Moreover, 
since the primary aim of GDS is to understand drug use and not gender differences, the 
volunteer bias that may have affected the specialist research that we mention is unlikely to 
have influenced our findings (Eysenbach & Wyatt, 2002). 
GDS also reports the largest sample of non-binary people in the substance misuse literature 
and is the first study to offer disaggregated analysis for non-binary participants (Flentje, 
Bacca, & Cochran, 2015; Keuroghlian, Reisner, White, & Weiss, 2015). Given the increased 
need for help that the non-binary participants in this study demonstrated and the increasing 
incidence of self-reported non-binary gender identity (Sell, Goldberg, & Conron, 2015), our 
study is an important step forward in understanding respondents who want to use less and 
their potential treatment needs.  
Prior trans substance misuse research has been criticized for being dominated by studies 
from North America (Gilbert, Pass, Keuroghlian, Greenfield, & Reisner, 2018). The global 
samples presented here move toward a more general understanding of substance misuse 
help-seeking intentions among trans people, independent of country- or region-specific 
influences. However, this fails to capture the between-country variation in psychoactive 
substance use behaviors among trans people, which might relate to the acceptability of 
being trans in individual countries. Despite the large sample size in this study, the number of 
trans respondents would be too small to analyze accurately by country. As such, it was not 
possible for us to consider the cannabis legislation of individual nations and so we made a 
decision to consider cannabis separately from “illicit drugs” due to the large number of 
respondents reporting cannabis use.  
We recognize that this study is limited by its cross-sectional design and that the nature of 
these questions allow only for an introductory understanding of substance misuse help-
seeking among trans people. Moreover, it has not been possible to comment on help-
seeking intentions for opioid users, despite the global opioid crisis (Anderson, 2017). Data 
on opioid use was not collected in GDS 2018. We had to combine the GDS 2018 and GDS 
2019 datasets to have a sufficient number of trans respondents for meaningful comparison. 
As such, help-seeking intentions were only reported for substances considered in both GDS 
2018 and GDS 2019. 
 
4.4. Future research and clinical implications 
This work is novel and therefore needs to be replicated in similarly sized, and ideally more 
representative, samples. However, there is significant cost and difficulty associated with 
obtaining a representative sample of psychoactive substance users large enough to 
compare trans and cis respondents, particularly since psychoactive substance use and trans 
identity are both socially sensitive topics and highly stigmatized. 
The GDS 2021 will explore additional items relating to barriers to treatment-seeking, 
negative experiences within treatment, and individuals’ preferred method of support. The 
GDS 2021 will be useful to further understanding of the findings presented here. Qualitative 
work should also be conducted to gain a deeper understanding of the reasons why trans 
(particularly non-binary) people are reporting a greater desire for substance misuse help 
compared to their cis counterparts. Our research should be supplemented by research, both 
qualitative and quantitative, that seeks to identify which barriers and facilitators influence 
trans peoples’ engagement with substance misuse services, both across the trans 
community and within particular subgroups; e.g., trans men.  
The finding that trans people may be more likely to want help for substance misuse than cis 
people reinforces how worrying a finding it is that as few as 5% of substance misuse service 
providers report formal education surrounding the needs of trans clients (Rachlin et al., 
2008). As an introduction to concepts of (trans)gender as they relate to health, we 
recommend the following introductory texts: American Psychological Association (2015); 
Richards, Bouman, & Barker (2017); and Vincent (2018). Following an introduction to these 
concepts, we recommend formal training for service providers, with the aim of empowering 
them to: a) communicate sensitively with trans clients, with appropriate language and 
pronoun use; b) develop an awareness of the violence that trans people face, including 
within healthcare settings (Lyons et al., 2015; Reisner et al., 2015); c) offer trans people 
access to single-gender spaces that reflect their lived gender; d) facilitate the development 
of trans-specific peer-support groups; and e) work collaboratively with trans people to 
develop service-user informed psychosocial interventions. In addition, we recommend the 
use of the two-stage approach to recording gender in initial assessments, in the clinical 
setting  (Bauer et al., 2017; Sausa et al., 2009). Recording gender in this way demonstrates 
cultural competence and allows trans people to disclose their identity to ensure that they 
receive the benefits of the aforementioned training.  
 
5. Conclusions 
This study suggests that trans people may have a greater need for substance misuse 
services than their cis counterparts. Considering this finding in the context of potentially 
stigmatizing general substance misuse services and a paucity of specialist alternatives, 
there is a need for both clinicians and researchers to move beyond the current cisnormative 
binary conception of gender so that the needs of substance using trans people can be 
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Gender group Number of participants 
Female Female Cis woman 64,319 
Male Male Cis man 118,157 
Male Female Trans woman* 353 



















Table 2: Percentage of GDS respondents who report wanting to use alcohol and other drugs less often, or get help with using less, by gender.  
 
Cis men  Cis women Trans men Trans women Non-binary χ2 (df = 4) 
Want to drink less alcohol 34.0% (35,243)a 30.8% (17,774)b 28.9% (87)a,b 30.1% (88)a,b 33.3% (512)a,b 178.1*** 
Want help to drink less alcohol 8.5% (2,947)a 7.9% (1,384)a 11.5% (10)a,b 10.5% (9)a,b 14.0% (71)b 25.1*** 
Want to use less cannabis 30.9% (18,069)a 26.5% (6,424)b 23.2% (43)a,b 21.9% (39)a,b 28.7% (290)a,b 172.4*** 
Want help to use less cannabis 12.3% (1,981)a 13.1% (728)a 23.1% (9)a,b 27.0% (10)a,b 21.3% (56)b 27.0*** 
Want to use less illicit drugs 46.7% (15,554)a 45.9% (6,895)a 47.1% (41)a 35.3% (41)a 41.5% (252)a 14.1** 
Want help to use less illicit drugs 10.6% (1,046)a 10.9% (415)a 13.0% (3)a,b 30.0% (9)b 15.1% (27)a,b 11.7* 
Notes: *p<0.05; **p<0.01; ***p<0.0001; df: degrees of freedom; each superscript letter (a,b,c) indicates a group which differs significantly from any group not denoted with the same 








i These composite variables were necessary because the number of responses for individual 
substances was too small to allow for meaningful analysis. For example, the question “Would you like 
help to use less cocaine over the next 12 months?” had only 82 trans respondents (trans men n=10, 
trans women n=8, non-binary n=64). Similarly, the question “Would you like help to use less 
methamphetamine over the next 12 months?” had 35 trans respondents (trans men n=3, trans women 
n=6, non-binary n=26). 
                                                          
